Sign inJoin waitlistJoin the waitlist

Ralph Salloum

Director, Pediatric Neuro-Oncology Survivorship · Mass General Brigham

Credentials: · · · · · · ·

History

Mass General Brigham
Present

Cincinnati Children's Hospital Medical Center
2015–2016
Pediatric Hematology Oncology
Cincinnati Children's Hospital Medical Center
2012–2015
Internal Medicine
2009–2012
Pediatrics
Children's Hospital of Michigan
2006–2009
American Univ of Beirut, Beirut, Lebanon
2002–2006

Research

Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics
Acta Neuropathologica Communications · 2016 · 131 citations
Late Morbidity and Mortality Among Medulloblastoma Survivors Diagnosed Across Three Decades: A Report From the Childhood Cancer Survivor Study
Journal of Clinical Oncology · 2019 · First of 14 authors · 105 citations
A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium…
Journal of Neuro-Oncology · 2016 · First of 19 authors · 82 citations

Maryam Fouladi
17 papers
Peter de Blank
12 papers
Trent Hummel
11 papers
Charles Stevenson
9 papers
LH
Lindsey Hoffman
9 papers
Margot Lazow
9 papers · 1 as a fellow
MD
Mariko Dewire-Schottmiller
9 papers
Ashley Margol
7 papers
CF
Christine Fuller
7 papers
Natasha Smiley
7 papers
James Leach
6 papers
LM
Lili Miles
6 papers

Grants

Phase I/II Study of 177Lu-DOTATATE in Children and Young Adults with Recurrent/Progressive High-Grade CNS Tumors and Meningiomas Which Express Somatostatin Type 2A Receptors [9/24/21 IND]
Food and Drug Administration · R01
PI · $1.3M · Research Inst Nationwide Children's Hosp
2022–2028

Clinical trials

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Principal investigator · Recruiting · Phase 3
Children's Oncology Group
2023–2029
Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
Principal investigator · Active not recruiting · Phase 1
National Cancer Institute (NCI)
2018–2027
Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery
Study chair · Terminated · Phase 1, Phase 2
Pediatric Brain Tumor Consortium
2019–2025